LymphomaNCT01078350
Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy
An observational study of Lymphoma and Hodgkin Disease, run by Stanford University at 1 site in United States.
Trial summary
This study is designed to collect tissue samples that may aid in the treatment and learning about various oncology diagnosis. Read more about this study
- Who is it for?
- Ages Up to 21 years
- Conditions the study is for
- Lymphoma, Hodgkin Disease
- What is being tested?
- tumor tissue aspiration and phlebotomy
- Type of treatment
- Surgery or procedure
- How many people
- 93 participants
- Where
- 1 siteUnited States
- Study dates
- May 2004to 4 Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study.
Who may be able to join
- Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study.
Who cannot join
- None.
Trial locations and contacts
1 site in 1 country.
United States1 site
Stanford University School of Medicine
Stanford, California, 94305
About this study
This study is designed to collect tissue samples that may aid in the treatment and learning about various oncology diagnosis.
Read the detailed description
The purpose of this study is to provide a mechanism to obtain tissue specimens to be used for experimental studies before the exact histologic diagnosis is known.
- Conditions
- Lymphoma, Hodgkin Disease
- Being tested
- tumor tissue aspiration, phlebotomy
- Keywords
- Lymphoma, Hodgkin Disease
- Medical subject headings
- Lymphoma, Hodgkin Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tumor tissue aspirationProcedure or surgery
phlebotomyProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Further analysis
Measured: at collection time
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2010 (estimated)
- Study startMay 2004
- Primary completion4 Dec 2015
- Study completion4 Dec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LymphomaStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 93 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dr. Neyssa Marina, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01078350
- Sponsor's protocol ID
- BANKPEDSTS0001
- Other IDs
- 80003, SU-11052007-794
- Status last verified
- Nov 2017
- First submitted
- 26 Feb 2010
- Last updated
- 20 Nov 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy
- ClinicalTrials.gov ID
- NCT01078350
- Acronym / sponsor ID
- BANKPEDSTS0001
- Conditions
- Lymphoma, Hodgkin Disease
- Keywords
- Lymphoma, Hodgkin Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 93 participants (actual)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- May 2004 (actual)
- Primary completion
- 4 Dec 2015 (actual)
- Study completion
- 4 Dec 2015 (actual)
- First posted
- 2 Mar 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to collect tissue samples that may aid in the treatment and learning about various oncology diagnosis.
Detailed description
The purpose of this study is to provide a mechanism to obtain tissue specimens to be used for experimental studies before the exact histologic diagnosis is known.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- Up to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study.
Key inclusion criteria (1 listed)
- Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study.
Key exclusion criteria (1 listed)
- None.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tumor tissue aspiration | Procedure or surgery | – |
| phlebotomy | Procedure or surgery | – |
Primary outcome
Further analysis
Time frame: at collection time
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2017.
Related trials for Lymphoma
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Not yet recruitingPhase 1
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Neyssa Marina principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lymphoma and Hodgkin Disease, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Further analysis (time frame: at collection time). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2017.